|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP3302482A4
(en)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
WO2017197055A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
US20180072711A1
(en)
|
2016-09-15 |
2018-03-15 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
EP3532464A4
(en)
|
2016-10-28 |
2020-07-08 |
Icahn School of Medicine at Mount Sinai |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
|
|
EP3535265A4
(en)
|
2016-11-01 |
2020-07-08 |
Arvinas, Inc. |
PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
|
|
PL3689868T3
(pl)
|
2016-12-01 |
2024-03-11 |
Arvinas Operations, Inc. |
Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych
|
|
WO2018118598A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
CN117510491A
(zh)
|
2016-12-23 |
2024-02-06 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
CN110612294B
(zh)
|
2017-01-31 |
2024-01-16 |
阿尔维纳斯运营股份有限公司 |
人小脑蛋白配体和包含其的双官能化合物
|
|
KR102014478B1
(ko)
*
|
2017-05-12 |
2019-08-26 |
한국화학연구원 |
신규한 피페리딘-2,6-디온 유도체 및 이의 용도
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
PL3651766T3
(pl)
|
2017-07-10 |
2025-03-03 |
Celgene Corporation |
4-(4-(4-(((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-4-ylo)oksy)metylo)benzylo)piperazyn-1-ylo)-3-fluorobenzonitryl jako związek przeciwproliferacyjny
|
|
EP3679026A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Glutarimide
|
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
|
EP3679028A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydroquinolinones
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
|
IL295603B2
(en)
|
2017-09-22 |
2024-03-01 |
Kymera Therapeutics Inc |
Protein degraders and uses thereof
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADATION AND DEGRADATION AGENTS FOR TARGETED PROTEIN DEGRADATION
|
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11220515B2
(en)
|
2018-01-26 |
2022-01-11 |
Yale University |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2019177902A1
(en)
|
2018-03-10 |
2019-09-19 |
Yale University |
Modulators of btk proteolysis and methods of use
|
|
CN111936498B
(zh)
|
2018-03-26 |
2024-04-16 |
诺华股份有限公司 |
N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
|
|
WO2019191112A1
(en)
|
2018-03-26 |
2019-10-03 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
|
DK3774789T3
(da)
|
2018-04-01 |
2025-06-10 |
Arvinas Operations Inc |
BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
|
|
MX2020010420A
(es)
|
2018-04-04 |
2020-12-11 |
Arvinas Operations Inc |
Moduladores de la proteólisis y métodos asociados de uso.
|
|
MX2020010571A
(es)
*
|
2018-04-13 |
2021-01-08 |
Arvinas Operations Inc |
Ligandos de cereblon y compuestos bifuncionales que los comprenden.
|
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
MX2020011183A
(es)
|
2018-04-23 |
2020-11-12 |
Celgene Corp |
Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
|
|
MX2020012066A
(es)
|
2018-05-14 |
2021-04-28 |
Nuvation Bio Inc |
Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CN113166100A
(zh)
*
|
2018-06-29 |
2021-07-23 |
达纳-法伯癌症研究所有限公司 |
免疫调节性化合物
|
|
EP3814380A4
(en)
*
|
2018-06-29 |
2022-06-15 |
Dana Farber Cancer Institute, Inc. |
BISPECIFIC DEGRADATION PRODUCTS
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
DK3820573T3
(da)
|
2018-07-10 |
2023-10-23 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
JP7515175B2
(ja)
|
2018-07-31 |
2024-07-12 |
ファイメクス株式会社 |
複素環化合物
|
|
CN108774215A
(zh)
*
|
2018-08-15 |
2018-11-09 |
翟学旭 |
含氮杂环类衍生物及其在视网膜新生血管疾病中的应用
|
|
CN112912376A
(zh)
|
2018-08-20 |
2021-06-04 |
阿尔维纳斯运营股份有限公司 |
用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
|
|
IL280984B2
(en)
|
2018-08-22 |
2025-02-01 |
Cullgen Shanghai Inc |
Tropomyosin receptor kinase (TRK) inhibitor compounds and methods of use
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
WO2020048547A1
(zh)
*
|
2018-09-07 |
2020-03-12 |
南京明德新药研发有限公司 |
三环并呋喃取代哌啶二酮类化合物
|
|
EP3886904A4
(en)
|
2018-11-30 |
2022-07-13 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
KR20210098960A
(ko)
*
|
2018-12-03 |
2021-08-11 |
다나-파버 캔서 인스티튜트 인크. |
Helios의 소분자 분해제 및 사용 방법
|
|
AU2019403207B2
(en)
|
2018-12-19 |
2025-06-05 |
Celgene Corporation |
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
|
|
US11325889B2
(en)
|
2018-12-19 |
2022-05-10 |
Celgene Corporation |
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
|
|
CN120698985A
(zh)
*
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
EP3917916A4
(en)
*
|
2019-01-30 |
2022-12-14 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
EP3922632A4
(en)
*
|
2019-02-07 |
2023-02-15 |
Korea Research Institute of Chemical Technology |
DEGRADATION AGENT THAT INDUCES DEGRADATION OF A TARGET EED PROTEIN, METHOD FOR ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH EED, EZH2 OR PRC2 USING SUCH AGENT AS THE ACTIVE SUBSTANCE
|
|
US12479817B2
(en)
|
2019-02-15 |
2025-11-25 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2020172655A1
(en)
*
|
2019-02-23 |
2020-08-27 |
New York University |
Photoswitchable protacs and synthesis and uses thereof
|
|
CA3135802A1
(en)
|
2019-04-05 |
2020-10-08 |
Kymera Therapeutics, Inc. |
Stat degraders and uses thereof
|
|
WO2020206608A1
(en)
*
|
2019-04-09 |
2020-10-15 |
Ranok Therapeutics (Hangzhou) Co., Ltd. |
Methods and compositions for targeted protein degradation
|
|
WO2020214555A1
(en)
|
2019-04-16 |
2020-10-22 |
Northwestern University |
Bifunctional compounds comprising apcin-a and their use in the treatment of cancer
|
|
AU2020259946B2
(en)
*
|
2019-04-18 |
2023-05-18 |
Hinova Pharmaceuticals Inc. |
A class of bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof
|
|
CA3137916A1
(en)
*
|
2019-05-06 |
2020-11-12 |
Ichan School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of hpk1
|
|
MX2021013774A
(es)
|
2019-05-14 |
2021-12-10 |
Nuvation Bio Inc |
Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
|
|
US20230087825A1
(en)
*
|
2019-06-10 |
2023-03-23 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020252397A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Baylor College Of Medicine |
Small molecule proteolysis-targeting chimeras and methods of use thereof
|
|
US20210009718A1
(en)
|
2019-06-25 |
2021-01-14 |
Gilead Sciences, Inc. |
FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
|
|
CN119954801A
(zh)
*
|
2019-07-17 |
2025-05-09 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
MX2022002415A
(es)
*
|
2019-08-26 |
2022-03-22 |
Arvinas Operations Inc |
Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
|
|
AU2020336381A1
(en)
*
|
2019-08-27 |
2022-03-03 |
The Regents Of The University Of Michigan |
Cereblon E3 ligase inhibitors
|
|
JP7209897B2
(ja)
*
|
2019-09-12 |
2023-01-20 |
メッドシャイン ディスカバリー インコーポレイテッド |
Ｃｒｂｎタンパク質モジュレーターとしての二環式化合物
|
|
TW202123942A
(zh)
*
|
2019-09-16 |
2021-07-01 |
瑞士商諾華公司 |
Ｂｒｄ９雙官能基降解劑及其使用方法
|
|
WO2021053555A1
(en)
*
|
2019-09-16 |
2021-03-25 |
Novartis Ag |
Glue degraders and methods of use thereof
|
|
EP4038066A1
(en)
|
2019-10-01 |
2022-08-10 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
CN119019369A
(zh)
|
2019-10-17 |
2024-11-26 |
阿尔维纳斯运营股份有限公司 |
含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
|
|
TW202131930A
(zh)
|
2019-11-13 |
2021-09-01 |
美商諾維雪碧歐公司 |
抗癌核荷爾蒙受體標靶化合物
|
|
CN110885332B
(zh)
*
|
2019-12-06 |
2022-03-18 |
中国人民解放军第二军医大学 |
一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
|
|
GB201918414D0
(en)
*
|
2019-12-13 |
2020-01-29 |
Z Factor Ltd |
Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
|
|
TW202136251A
(zh)
|
2019-12-17 |
2021-10-01 |
美商凱麥拉醫療公司 |
Irak降解劑及其用途
|
|
EP4076001A4
(en)
*
|
2019-12-17 |
2023-12-20 |
Orionis Biosciences, Inc. |
MODULATION OF PROTEIN DEGRADATION
|
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
CN115175901B
(zh)
|
2019-12-19 |
2024-03-22 |
阿尔维纳斯运营股份有限公司 |
用于雄激素受体的靶向降解的化合物和方法
|
|
CN114901277B
(zh)
|
2019-12-20 |
2024-05-17 |
C4医药公司 |
用于egfr降解的异吲哚啉酮和吲唑化合物
|
|
BR112022012385A2
(pt)
|
2019-12-23 |
2022-08-30 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
Método de preparação e aplicação de composto de agente de degradação de proteínas
|
|
CA3162502A1
(en)
|
2019-12-23 |
2021-07-01 |
Yi Zhang |
Smarca degraders and uses thereof
|
|
EP4090649A4
(en)
*
|
2020-01-14 |
2024-09-04 |
The Trustees of Columbia University in the City of New York |
COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES
|
|
WO2021143816A1
(zh)
*
|
2020-01-16 |
2021-07-22 |
江苏恒瑞医药股份有限公司 |
稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
|
|
WO2021143822A1
(zh)
*
|
2020-01-16 |
2021-07-22 |
江苏恒瑞医药股份有限公司 |
并环酰亚胺类衍生物、其制备方法及其在医药上的应用
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
MX2022009947A
(es)
|
2020-02-14 |
2022-11-07 |
Jounce Therapeutics Inc |
Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
EP4110772A4
(en)
|
2020-02-26 |
2024-04-03 |
Cullgen (Shanghai), Inc. |
TROPOMYOSIN-RELATED KINASE RECEPTOR (TRK) DEGRADING COMPOUNDS AND METHODS OF USE
|
|
EP3875456A1
(en)
*
|
2020-03-02 |
2021-09-08 |
Technische Universität Darmstadt |
Hetero-bifunctional proteolysis-targeting chimeras (protacs) for the selective degradation of fk506-binding proteins (fkbps)
|
|
CN111249276B
(zh)
*
|
2020-03-05 |
2021-07-13 |
南京巴傲得生物科技有限公司 |
吲哚布洛芬制备cbp溴区抑制试剂的用途
|
|
MX2022010952A
(es)
|
2020-03-05 |
2022-10-07 |
C4 Therapeutics Inc |
Compuestos para la degradacion dirigida de brd9.
|
|
WO2021175317A1
(zh)
*
|
2020-03-06 |
2021-09-10 |
正大天晴药业集团股份有限公司 |
一种作用于crbn蛋白的三并环类化合物的结晶及其制备方法
|
|
CN113387931A
(zh)
*
|
2020-03-13 |
2021-09-14 |
四川海思科制药有限公司 |
一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
|
|
US20230158152A1
(en)
*
|
2020-03-17 |
2023-05-25 |
Medshine Discovery Inc. |
Proteolysis regulator and method for using same
|
|
JP2023518202A
(ja)
*
|
2020-03-18 |
2023-04-28 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
Ｐｅｔトレーサーｐｂｂ３に基づく異常タウの標的化ディグレーダー
|
|
MX2022011602A
(es)
|
2020-03-19 |
2023-01-04 |
Kymera Therapeutics Inc |
Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos.
|
|
WO2021194318A1
(en)
*
|
2020-03-27 |
2021-09-30 |
Uppthera |
Plk1 selective degradation inducing compound
|
|
WO2021210878A1
(ko)
*
|
2020-04-17 |
2021-10-21 |
광주과학기술원 |
Crbn 결합 펩티드 및 이를 이용한 알츠하이머 병 예방 또는 치료용 조성물
|
|
US20240270780A1
(en)
*
|
2020-04-29 |
2024-08-15 |
Tai Bi Di Pharmaceutical Technology (Shijiazhuang) Co. Ltd |
Proteolysis targeting compound with tissue targeting capability and use thereof
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
US20230357249A1
(en)
*
|
2020-05-14 |
2023-11-09 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders with a tricyclic cereblon ligand
|
|
EP4153175A4
(en)
*
|
2020-05-21 |
2024-06-05 |
Dana-Farber Cancer Institute, Inc. |
PIPERIDINE-2,6-DIONES USED AS HELIOS SMALL MOLECULE DEGRADING AGENTS AND METHODS OF USE
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
WO2021249534A1
(zh)
*
|
2020-06-12 |
2021-12-16 |
上海济煜医药科技有限公司 |
酞嗪酮类化合物及其制备方法和医药用途
|
|
CA3178172A1
(en)
*
|
2020-06-22 |
2021-12-30 |
Eric Fischer |
Protein tag to induce ligand dependent degradation of protein/protein-fusions
|
|
KR102559329B1
(ko)
*
|
2020-07-02 |
2023-07-25 |
포항공과대학교 산학협력단 |
신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물
|
|
EP4180427A4
(en)
*
|
2020-07-09 |
2024-08-21 |
Xizang Haisco Pharmaceutical Co., Ltd. |
COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS AND THEIR PHARMACEUTICAL USES
|
|
US12122763B2
(en)
*
|
2020-07-21 |
2024-10-22 |
Ubix Therapeutics, Inc. |
Substituted piperidines for androgen receptor degradation
|
|
KR20220014952A
(ko)
*
|
2020-07-29 |
2022-02-08 |
한국화학연구원 |
안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
|
|
IL300308A
(en)
*
|
2020-08-03 |
2023-04-01 |
Captor Therapeutics S A |
Low molecular weight protein complexes and their applications
|
|
KR20230050375A
(ko)
*
|
2020-08-05 |
2023-04-14 |
상하이 리딩택 파마슈티컬 코., 엘티디. |
단백질 표적화 및 분해용 화합물, 이의 제조방법 및 용도
|
|
WO2022032026A1
(en)
|
2020-08-05 |
2022-02-10 |
C4 Therapeutics, Inc. |
Compounds for targeted degradation of ret
|
|
JP2023539663A
(ja)
|
2020-08-28 |
2023-09-15 |
アルビナス・オペレーションズ・インコーポレイテッド |
急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
|
|
WO2022048605A1
(zh)
*
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
BR112023004656A2
(pt)
|
2020-09-14 |
2023-05-09 |
Arvinas Operations Inc |
Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
|
|
CN114181277A
(zh)
*
|
2020-09-15 |
2022-03-15 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
MX2023003114A
(es)
|
2020-09-23 |
2023-03-23 |
St Jude Childrens Res Hospital Inc |
Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-i l)arilsulfonamida sustituidos como moduladores de la proteina cereblon.
|
|
MX2023003564A
(es)
|
2020-09-30 |
2023-04-04 |
Astrazeneca Ab |
Compuestos y su uso en el tratamiento del cancer.
|
|
JP2023545509A
(ja)
*
|
2020-10-14 |
2023-10-30 |
シーフォー セラピューティクス， インコーポレイテッド |
医学的療法のための、ネオ基質を分解する三環式化合物
|
|
US12419960B2
(en)
|
2020-10-21 |
2025-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
|
|
CN114621231B
(zh)
*
|
2020-12-14 |
2025-09-12 |
杭州中美华东制药有限公司 |
一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
MX2023008296A
(es)
|
2021-01-13 |
2023-09-29 |
Monte Rosa Therapeutics Inc |
Compuestos de isoindolinona.
|
|
US20240132482A1
(en)
*
|
2021-02-04 |
2024-04-25 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Benzo seven-membered ring bifunctional compound and application thereof
|
|
IL304905A
(en)
|
2021-02-15 |
2023-10-01 |
Kymera Therapeutics Inc |
IRAK4 joints and their uses
|
|
US12171768B2
(en)
|
2021-02-15 |
2024-12-24 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
US20240383868A1
(en)
*
|
2021-02-19 |
2024-11-21 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
JP2024509625A
(ja)
*
|
2021-03-15 |
2024-03-04 |
ノバルティス アーゲー |
ベンゾイソオキサゾール誘導体及びその使用
|
|
IL306010A
(en)
|
2021-03-23 |
2023-11-01 |
Nuvation Bio Inc |
Anticancer compounds against the nuclear hormone receptor
|
|
MX2023011166A
(es)
*
|
2021-03-29 |
2023-09-29 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
|
|
CN115141179B
(zh)
*
|
2021-03-31 |
2024-09-13 |
江苏恒瑞医药股份有限公司 |
一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
|
|
US20240217968A1
(en)
*
|
2021-03-31 |
2024-07-04 |
Duke Street Bio Limited |
Pharmaceutical compound
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
WO2022221673A1
(en)
|
2021-04-16 |
2022-10-20 |
Arvinas Operations, Inc. |
Modulators of bcl6 proteolysis and associated methods of use
|
|
CN113603676B
(zh)
*
|
2021-04-28 |
2022-05-24 |
浙江工业大学 |
基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用
|
|
AU2022269568A1
(en)
*
|
2021-05-03 |
2023-11-16 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
IL308219A
(en)
|
2021-05-05 |
2024-01-01 |
Biogen Ma Inc |
Compounds to Target Broton Tyrosine Kinase Degradation
|
|
TW202309030A
(zh)
|
2021-05-07 |
2023-03-01 |
美商凱麥拉醫療公司 |
Cdk2降解劑及其用途
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
KR102474999B1
(ko)
*
|
2021-05-26 |
2022-12-07 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
KR102489160B1
(ko)
*
|
2021-05-26 |
2023-01-18 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
CN116323619A
(zh)
*
|
2021-05-26 |
2023-06-23 |
因诺库尔治疗公司 |
哌啶二酮衍生物
|
|
WO2022250350A1
(ko)
*
|
2021-05-26 |
2022-12-01 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
WO2022255890A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255889A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255888A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
AU2022290851A1
(en)
|
2021-06-08 |
2023-11-23 |
C4 Therapeutics, Inc. |
Therapeutics for the degradation of mutant braf
|
|
EP4359407A4
(en)
*
|
2021-06-25 |
2025-04-30 |
Celgene Corporation |
CEREBLON-BINDING COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT USING THEM
|
|
KR20240025613A
(ko)
*
|
2021-06-25 |
2024-02-27 |
셀진 코포레이션 |
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
|
|
KR20240026946A
(ko)
*
|
2021-06-25 |
2024-02-29 |
셀진 코포레이션 |
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
|
|
WO2023283130A1
(en)
|
2021-07-04 |
2023-01-12 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
US20250018046A1
(en)
|
2021-07-07 |
2025-01-16 |
Biogen Ma Inc |
Compounds for targeting degradation of irak4 proteins
|
|
TW202321236A
(zh)
|
2021-07-07 |
2023-06-01 |
美商百健Ｍａ公司 |
用於靶向ｉｒａｋ４蛋白降解之化合物
|
|
TW202317546A
(zh)
|
2021-07-09 |
2023-05-01 |
美商普萊克斯姆公司 |
調節ikzf2之芳基化合物及醫藥組合物
|
|
EP4157850A4
(en)
*
|
2021-08-10 |
2024-11-20 |
Uppthera, Inc. |
Novel plk1 degradation inducing compound
|
|
EP4385985A1
(en)
*
|
2021-08-11 |
2024-06-19 |
Xizang Haisco Pharmaceutical Co., Ltd. |
Heterocyclic derivative, and composition and pharmaceutical use thereof
|
|
CR20240080A
(es)
|
2021-08-18 |
2024-04-09 |
Gilead Sciences Inc |
Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos
|
|
JP2024531319A
(ja)
*
|
2021-08-23 |
2024-08-29 |
シャンハイ リーディングタック ファーマシューティカル カンパニー，リミテッド |
Ｉｒａｋ４分解剤及びその製造方法並びに応用
|
|
US20240365736A1
(en)
|
2021-09-01 |
2024-11-07 |
Oerth Bio Llc |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115746058A
(zh)
*
|
2021-09-03 |
2023-03-07 |
南京知和医药科技有限公司 |
一种多环化合物在制备抗肿瘤药物方面的用途
|
|
US20240409528A1
(en)
*
|
2021-10-01 |
2024-12-12 |
Dana-Farber Cancer Institute, Inc. |
Binders of cereblon and methods of use thereof
|
|
WO2023059792A1
(en)
*
|
2021-10-06 |
2023-04-13 |
C4 Thrapeutics, Inc. |
Coronavirus non-structural protein 3 degrading compounds
|
|
CA3235512A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Xiaobao Yang |
Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications
|
|
JP2024539252A
(ja)
|
2021-10-28 |
2024-10-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ピリジジン－３（２ｈ）－オン誘導体
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
WO2023081224A1
(en)
*
|
2021-11-03 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein
|
|
US20250127906A1
(en)
*
|
2021-11-05 |
2025-04-24 |
University Of South Carolina |
Small-molecule degraders of cdk8 and cdk19
|
|
JP2024541480A
(ja)
|
2021-11-24 |
2024-11-08 |
アルビナス・オペレーションズ・インコーポレイテッド |
Ｂｒｍ標的化化合物及び関連使用方法
|
|
EP4436965A1
(en)
|
2021-11-24 |
2024-10-02 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
EP4438603A4
(en)
|
2021-11-25 |
2025-06-11 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
EP4452415A1
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114085213B
(zh)
*
|
2022-01-20 |
2022-03-25 |
苏州国匡医药科技有限公司 |
一种arv-471的制备方法
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
JP2025504059A
(ja)
|
2022-01-31 |
2025-02-06 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋデグレーダー及びその使用
|
|
HUE069263T2
(hu)
|
2022-03-17 |
2025-02-28 |
Gilead Sciences Inc |
Ikarosz cink-ujj család degradálói és azok alkalmazása
|
|
EP4499628A1
(en)
*
|
2022-03-24 |
2025-02-05 |
GlaxoSmithKline Intellectual Property Development Limited |
2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs
|
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2023212599A2
(en)
*
|
2022-04-26 |
2023-11-02 |
Endotarget Inc. |
Compounds and methods for targeted degradation of estrogen receptors
|
|
CA3249074A1
(en)
|
2022-06-06 |
2023-12-14 |
C4 Therapeutics, Inc. |
BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS
|
|
CA3259653A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Anhorn Medicines Co., Ltd. |
BIFUNCTIONAL COMPOSITE AND PHARMACEUTICAL COMPOSITION COMPRISING IT, AND METHOD OF TREATMENT OF ANDROGEN RECEPTOR-ASSOCIATED DISEASES USING IT
|
|
PE20250758A1
(es)
|
2022-07-01 |
2025-03-13 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
EP4554948A1
(en)
*
|
2022-07-12 |
2025-05-21 |
Regents of the University of Michigan |
Tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
CN116496253B
(zh)
*
|
2022-08-19 |
2024-10-11 |
中国人民解放军军事科学院军事医学研究院 |
c-MET蛋白靶向降解剂及其医药应用
|
|
CN115089588A
(zh)
*
|
2022-08-22 |
2022-09-23 |
云南大学 |
达沙布韦作为e3连接酶新型配体构建protac的应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054953A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054955A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024051766A1
(zh)
*
|
2022-09-08 |
2024-03-14 |
标新生物医药科技(上海)有限公司 |
基于cereblon蛋白设计的分子胶化合物及其应用
|
|
KR20250099113A
(ko)
|
2022-09-09 |
2025-07-01 |
이노보 테라퓨틱스 인코포레이티드 |
CK1α 및 DUAL CK1α/GSPT1 분해 화합물
|
|
WO2024056005A1
(zh)
*
|
2022-09-14 |
2024-03-21 |
先声再明医药有限公司 |
多并环类化合物及其用途
|
|
WO2024064316A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 inhibitors and uses thereof
|
|
WO2024073475A1
(en)
*
|
2022-09-27 |
2024-04-04 |
Oncopia Therapeutics, Inc. D/B/A Proteovant Therapeutics, Inc. |
Cereblon ligands and uses thereof
|
|
WO2024067781A1
(zh)
*
|
2022-09-29 |
2024-04-04 |
江苏恒瑞医药股份有限公司 |
一种四氢萘类衍生物的可药用盐、晶型及制备方法
|
|
WO2024067793A1
(zh)
*
|
2022-09-29 |
2024-04-04 |
海南先声再明医药股份有限公司 |
一类稠环化合物及其用途
|
|
CN117801051A
(zh)
*
|
2022-09-30 |
2024-04-02 |
苏州德亘生物医药有限公司 |
一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
|
|
WO2024091975A1
(en)
|
2022-10-24 |
2024-05-02 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
KR20240076745A
(ko)
*
|
2022-11-22 |
2024-05-30 |
주식회사 이노큐어테라퓨틱스 |
신규한 c-MET 단백질 리간드를 포함하는 디그레이더 및 이를 포함하는 약학 조성물
|
|
CN120584116A
(zh)
*
|
2022-11-22 |
2025-09-02 |
因诺库尔治疗公司 |
用于使brd蛋白降解的降解剂和含有其的药物组合物
|
|
KR20240075764A
(ko)
*
|
2022-11-22 |
2024-05-29 |
주식회사 이노큐어테라퓨틱스 |
cMET 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
|
|
KR20250130610A
(ko)
*
|
2022-12-06 |
2025-09-02 |
캡터 테라퓨틱스 에스.에이. |
유비퀴틴 리가제 및 표적 mcl-1 단백질에 결합하는 이작용성 화합물을 사용하는 표적화된 단백질 분해
|
|
WO2024123195A1
(en)
*
|
2022-12-06 |
2024-06-13 |
Captor Therapeutics S.A. |
Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
KR20250122479A
(ko)
|
2022-12-22 |
2025-08-13 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
TWI882643B
(zh)
*
|
2023-01-16 |
2025-05-01 |
大陸商南京明德新藥研發有限公司 |
取代的苯並七元環化合物及其應用
|
|
US12448399B2
(en)
|
2023-01-26 |
2025-10-21 |
Arvinas Operations, Inc. |
Cereblon-based KRAS degrading PROTACs and uses related thereto
|
|
EP4665720A2
(en)
*
|
2023-02-16 |
2025-12-24 |
Bristol-Myers Squibb Company |
Isoindolinone glutarimide and phenyl glutarimide analogs as degraders of ret kinase
|
|
CN116253719B
(zh)
*
|
2023-03-06 |
2025-04-01 |
苏州国匡医药科技有限公司 |
一种雌激素和雄激素受体双重降解剂及其应用
|
|
TW202508568A
(zh)
|
2023-04-07 |
2025-03-01 |
瑞典商阿斯特捷利康公司 |
Ｉｒａｋ４蛋白水解靶向嵌合體
|
|
US20240383922A1
(en)
|
2023-04-11 |
2024-11-21 |
Gilead Sciences, Inc. |
KRAS Modulating Compounds
|
|
AU2024256729A1
(en)
*
|
2023-04-20 |
2025-09-25 |
Auron Therapeutics, Inc. |
Technologies targeting cell states
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2024276994A1
(en)
|
2023-05-24 |
2025-10-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2024245408A1
(zh)
*
|
2023-06-01 |
2024-12-05 |
上海海和药物研究开发股份有限公司 |
用于雄激素受体依赖性疾病的苯并(杂)环烷基化合物
|
|
WO2024245444A1
(zh)
*
|
2023-06-01 |
2024-12-05 |
标新生物医药科技(上海)有限公司 |
氧代异吲哚啉基取代的四氢嘧啶二酮衍生物及其应用
|
|
WO2024245443A1
(zh)
*
|
2023-06-01 |
2024-12-05 |
标新生物医药科技(上海)有限公司 |
基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
|
|
TW202515566A
(zh)
|
2023-06-14 |
2025-04-16 |
瑞典商阿斯特捷利康公司 |
Ｓｍａｒｃａ２降解劑及其用途
|
|
WO2024256988A1
(en)
|
2023-06-14 |
2024-12-19 |
Astrazeneca Ab |
Smarca2 degraders and uses thereof
|
|
WO2024263781A1
(en)
*
|
2023-06-23 |
2024-12-26 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Targeted degraders of hiv-1 nef for the treatment of hiv disease
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025006753A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|
|
TW202502779A
(zh)
|
2023-06-30 |
2025-01-16 |
美商金橘生物科技公司 |
取代的雜芳族胺及其用途
|
|
WO2025006783A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras
|
|
WO2025011623A1
(zh)
*
|
2023-07-12 |
2025-01-16 |
上海壹迪生物技术有限公司 |
氰基喹啉类靶向蛋白降解分子、其制备方法和应用
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
CN119613374A
(zh)
*
|
2023-09-14 |
2025-03-14 |
中国科学院上海药物研究所 |
吲唑酮类化合物、其制备方法、药物组合物及其应用
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
WO2025061906A1
(en)
*
|
2023-09-22 |
2025-03-27 |
Glaxosmithkline Intellectual Property Development Limited |
Androgen receptor protacs
|
|
WO2025075693A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Purdue Research Foundation |
Shp2 degraders for cancer therapy
|
|
TW202523291A
(zh)
|
2023-11-02 |
2025-06-16 |
美商金橘生物科技公司 |
降解劑及其用途
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025114875A1
(en)
*
|
2023-12-01 |
2025-06-05 |
Astrazeneca Ab |
Er degraders and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025136129A1
(en)
*
|
2023-12-22 |
2025-06-26 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025212557A1
(en)
*
|
2024-04-01 |
2025-10-09 |
The Johns Hopkins University |
Delivery of aurora kinase inhibitors using nano-scale drug delivery platforms by covalent conjugation
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|